NE Washington News

Congressman Earl L. "Buddy" Carter, representing Georgia's First Congressional District, delivered a speech during a Subcommittee on Health hearing regarding the reauthorization of the Over-the-Counter Monograph Drug User Fee Program (OMUFA). The program, initially signed into law in March 2020, focuses on regulating over-the-counter (OTC) monograph drugs by enabling the Food and Drug Administration (FDA) to collect user fees dedicated to these drugs' activities.

Carter highlighted that this initiative aims to ensure Americans have access to quality and affordable OTC medications, which are used by almost 90% of the population for common ailments such as colds and headaches. The congressman emphasized the importance of the program for continuing innovations while maintaining FDA safety standards.

The current legislative authority for OMUFA is set to expire on September 30, 2025. Carter stressed the necessity for a timely reauthorization to extend the program and its benefits for another five-year term.

In his statement, Carter praised the efforts of Symrise, a company producing aroma molecules and fragrance ingredients, which overcome adversity by rebuilding its plant in Georgia after a 2022 fire. This move was described as a commitment to the local community.

Kevin Menzel, the President of Focus Consumer Healthcare, a subsidiary of Kobayashi Healthcare, was noted as an attendee of the hearing. The company has been expanding its presence significantly in Georgia, with investments that double its manufacturing capacity.

Successes such as those of Symrise and Kobayashi were cited by Carter as examples of how the OMUFA program can contribute to job creation and ensure access to safe OTC drugs. Carter expressed his anticipation for discussions with witnesses and meeting goals to reauthorize the program through regular procedures.